Clinical trial · no report yet · Phase 3
SAMETA
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
- NCT05043090 ↗
- Active not recruiting
- AstraZeneca
- 43 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 29 | |
| YouTube | 10 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Papillary Renal Cell Carcinoma
- Interventions
- savolitinib; durvalumab; sunitinib
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Arm C · Experimental
- Enrollment
- 148
- Primary outcomes
- Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib
- Sponsor
- AstraZeneca
- Start
- Oct 28, 2021
- Primary completion
- Dec 31, 2025
- Results posted
- No
- Registry record
- NCT05043090 · updated May 22, 2026
Publications
linked from the registry- Jackson-Spence F, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite FC, Ralph C, Srinivasan G, Mendez-Vidal MJ, Childress M, Li W, Boyle P, Gasco A, Markovets A, Hartmaier R, Ackerman C, Szabados BE, Priyadarshini G, Jamal F, Powles T, Suarez C. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. J Clin Oncol. 2026 Apr 20;44(12):1076-1082. doi: 10.1200/JCO-25-01840. Epub 2026 Mar 20. PubMed 41861260